drugset / Trial / NCT01714401

Nebulized Bronchodilators and Cardiac Repolarization

NCT01714401

Completed 50 enrolled Medical University of Gdansk
RandomizedParallel-groupTriple-blindOther

Summary

Patients of the ICU's often require bronchodilatory treatment due to bronchospasm caused by conditions like : acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) or asthma. The β2 adrenergic drugs are one of the most commonly used for this purpose. However it is known that they may cause tachycardia and may have substantial proarrhythmic effect. The investigators' aim is to estimate the influence of nebulized bronchodilatory drugs on selected electrophysiological parameters, whose changes are generally recognized as potentially increasing the risk of ventricular and supraventricular arrhythmias. Two drugs will be compared - salbutamol given in two doses and ipratropium bromide

Timeline

Start
2012-03
Primary completion
2013-05-30
Completion
2013-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salbutamol Unknown 2.5 mg Inhaled
Comparator Salbutamol Unknown 5 mg Inhaled

Indications

No indication recorded.